UPPSALA, Sweden, January 3 /PRNewswire/ -- Amic AB (Uppsala, Sweden) announced today that is has been granted a non-exclusive license under patent rights of Roche Diagnostics to commercialise a point-of-care (POC) test for NT-proBNP on the European market.
NT-proBNP is a key cardiac marker for a broad array of cardiovascular conditions, including the diagnosis and management of heart failure, and risk stratification of patients with acute coronary syndrome.
"This agreement with Roche Diagnostics marks a major milestone in Amic's development. The NT-proBNP test will be one of the first to be launched on our Forecast POC diagnostic system. The market for NT-proBNP testing is growing significantly in Europe, and we see great potential in the future for monitoring and managing the treatment of heart failure patients at the point of care," says Lars Gunneflo, CEO, Amic AB.
About Amic AB
Amic is a privately held POC diagnostic company with R&D and manufacture facilities based in Uppsala, Sweden. The company is developing the next generation of POC diagnostic tests using its proprietary microfluidic technology. The technology uses a moulded plastic device called the 4castchip(R), and a state-of-the-art optical detection system for precise and sensitive quantification of immunoassays.
The Company intends to launch the Forecast POC Diagnostic System with high-performance test kits for the cardiac markers NT-proBNP and cTnI.
The marker specific test cartridge contains the 4castchip(R) in a user friendly format for rapid analysis of whole-blood patient samples at the point of care. The Forecast Reader is a low-cost analyser designed for fail-safe operation in hospital and primary care settings with full connectivity to laboratory informations systems.
For more information please visit the company website at http://www.amic.se
|SOURCE Amic AB|
Copyright©2008 PR Newswire.
All rights reserved